New antibody combo tested for safety in healthy volunteers
NCT ID NCT05181683
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-stage study tested the safety of a combination of two antibodies (casirivimab and imdevimab) against the COVID-19 virus. It involved 45 healthy adults or those with stable chronic conditions. The goal was to see if the treatment is safe and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Regeneron Study Site
Miami, Florida, 33186, United States
-
Regeneron StudySite
Winter Park, Florida, 32789, United States
Conditions
Explore the condition pages connected to this study.